This paper is aimed at presenting SSRI online: an e-learning initiative started at the University of Milan (Italy) for the academic year 2004/05. The initiative consisted in offering an already existing three-years academic degree course (“laurea in Sicurezza dei Sistemi e delle Reti Informatiche SSRI”: a post-bachelor course on security of computer systems and networks) not only in the “tradit...

One of the most enigmatic problems in neurobiology is the apparent disconnect between rapid effects of serotonin reuptake inhibitors (SSRI) on extracellular serotonin (5-HT) levels and the slow onset of the therapeutic antidepressant effects of these drugs. Indeed, SSRIs increase extracellular 5-HT levels, but it is clear that subsequent neuroadaptations underlie the behavioral effects of these...

BACKGROUND Observational studies have found an increased risk of adverse effects such as hemorrhage, stroke, and increased mortality in patients taking selective serotonin reuptake inhibitors (SSRIs). The impact of prior use of these medications on outcomes in critically ill patients has not been previously examined. We performed a retrospective study to determine if preadmission use of SSRIs o...

OBJECTIVE To examine the use of selective serotonin reuptake inhibitors (SSRIs) among Danish women of childbearing age according to lifestyle factors. DESIGN Cross-sectional survey. SETTING The Central Denmark Region. PARTICIPANTS 4234 women (71.5% of the invited women) aged 25-44 years who participated in a public health survey in 2006. OUTCOME MEASURES Prevalence and prevalence ratios...

OBJECTIVE To evaluate attentional and activity behaviors in 4-year-olds following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. DESIGN Prospective cohort design. SETTING Tertiary care center. PARTICIPANTS Twenty-two 4-year-olds with prolonged prenatal SSRI medication exposure and 14 children without prenatal exposure. MAIN EXPOSURE Prenatal SSRI exposure. MAIN OUTCO...

First-line treatment of major depression includes administration of a selective serotonin reuptake inhibitor (SSRI), yet studies suggest that remission rates following two trials of an SSRI are <50%. The authors examine the putative biological substrates underlying "treatment resistant depression (TRD)" with the goal of elucidating novel rationales to treat TRD. We look at relevant articles fro...